Close
American Drug Delivery & Formulation Summit
Xylem

Sharp completes first phase of $23 million investment in its Bethlehem clinical services facility

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Study Identifies Tiered Manufacturing in Global Pharmaceutical Markets

A new research project from the Johns Hopkins Bloomberg...

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merckโ€™s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merckโ€™s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.
- Advertisement -

Sharp – a part of UDG Healthcare plc, a global leader in contract packaging and clinical supply services, has completed the first phase in the development of its new USD $23m state-of-the-art facility in Bethlehem, PA.

Sharp acquired the new Bethlehem facility for $14m in 2017 and has now completed a $2.5m relocation project, transferring the companyโ€™s clinical storage and distribution services from its Phoenixville site.

A second phase will see Sharp co-locate its fully integrated clinical services offering at the site when its packaging, manufacturing and analytical services move to the facility in late-2018, following a $6.4 million refit.

The Bethlehem development offers 1.5 million cubic feet of capacity on a 16-acre plot and will allow the company to increase pallet space for both cold and controlled-temperature storage by approximately 50%.

Frank Lis, president of Sharp Clinical Services, said: โ€œThe Bethlehem facility is a strategically important investment for Sharp. It will allow us to offer greater capacity, scalability and automation in response to growing demand for our services, as well as co-locating our clinical services at one facility. ย 

โ€œThis facility allows us to simultaneously support multiple large-scale phase III studies through to commercial launch.โ€
Investing in the Bethlehem site- has created 1.5 million cubic feet of new clinical services capacity in 2017 and is consistent with Sharpโ€™s strategy of capacity expansion to support current clients and meet future demand.

ABOUT SHARP
Sharp, a division of UDG healthcare, is a global leader in contract packaging and clinical services. Operating from state-of-the-art facilities across the US and Europe, Sharp has built an international reputation for delivering cost-effective blister packaging, bottling, pouches and stick packs, compliance packaging, formulation and manufacturing services, label design and printing. Sharp is also a world leader in โ€™Track and Traceโ€™ serialization services, which will require all prescription drugs to have a unique serial code for authentication and traceability.

For more information on Sharp and its solutions, visit www.sharpservices.com

World Pharma Today brings together the global pharmaceutical industry โ€” from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives โ€” through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

Study Identifies Tiered Manufacturing in Global Pharmaceutical Markets

A new research project from the Johns Hopkins Bloomberg...

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merckโ€™s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merckโ€™s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare โ€œmaximum fair pricesโ€ and Mostโ€‘Favouredโ€‘Nationโ€“style reference pricing are reshaping pharma margins and launch strategies.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป